The U.S. Food and Drug Administration has approved Zanvastro as the first drug to treat Alexander disease, a rare and progressive neurological condition that is often fatal. The disorder can impair motor skills, cognitive abilities, and involuntary functions such as heart rate and breathing.
Until now, no treatment had been available for the disease. The approval follows roughly thirty years of research efforts aimed at understanding the condition and developing a therapy that could alter its course.
Zanvastro's approval represents a significant milestone for patients and researchers, offering the first medical option where none previously existed. Further details about the drug's mechanism and clinical trial results were not included in the announcement.